CEO Doubles Down Despite the Carnage
Mary Szela just bought $102,776 of TLSI at $2.59 while technicals scream sell across every timeframe. This is her second buy recently, part of a cluster where 5 insiders have stepped in over the past month. The 90-day track record on this name is actually solid with insiders right 7 out of 10 times, but the short-term has been ugly. RSI at 35 suggests oversold conditions, but with all momentum pointing down, this is pure contrarian betting by the C-suite.
The Filing
| Ticker | TLSI |
| Company | TriSalus Life Sciences, Inc. |
| Insider | Mary Szela, CEO and President |
| Buy amount | $102,776 |
| Filing date | May 18, 2026 |
| Conviction | Interesting · 56/100 |
| Setup type | Oversold Bounce |
Ultimate members received this analysis in real time.